
FLOWPROMOTE: rosuvastatin plus ezetimibe shrank total coronary plaque 21% in 18 months
Louis shares a summary of the FLOWPROMOTE randomized study (JAMA Cardiology) comparing intensive LDL lowering with even more intensive lowering in 104 patients with established coronary disease. More LDL lowering produced more plaque regression, improving blood flow. Louis highlights the images showing the lumen opening up.


